CMAJ Open · 2016 · 85 citations · 31 references
PharmacyHealth PolicyInfectious DiseasesDrug Utilization ReviewHepatitis PharmacotherapyInfectious Disease PharmacotherapyAntiretroviral TherapyAntiviral PharmacologyAntiviral TherapyInterferon-based TherapyViral HepatitisViral Hepatitis TreatmentAntiviral Prescribing AppropriatenessAntiviral TreatmentDirect-acting Antiviral AgentsDirect-acting AntiviralsReimbursement AnalysisReimbursement MechanismsService ReimbursementUniversal Health Coverage Evaluation
BACKGROUND: In Canada, interferon-free, direct-acting antiviral hepatitis C virus (HCV) regimens are costly. This presents challenges for universal drug coverage of the estimated 220 000 people with chronic HCV infection nationwide. The study objective was to appraise criteria for reimbursement of 4 HCV direct-acting antivirals in Canada. METHODS: ombitasvir plus dasabuvir in the 10 provinces and 3 territories. Data were extracted from April 2015 to June 2016. The primary outcomes extracted from health ministerial websites were: 1) minimum fibrosis stage required, 2) drug and alcohol use restrictions, 3) HIV coinfection restrictions and 4) prescriber type restrictions. RESULTS: Overall, 85%-92% of provinces/territories limited access to patients with moderate fibrosis (Meta-Analysis of Histologic Data in Viral Hepatitis stage F2 or greater, or equivalent). There were no drug and alcohol use restrictions; however, several criteria (e.g., active injection drug use) were left to the discretion of the physician. Quebec did not reimburse simeprevir and sofosbuvir for people coinfected with HIV; no restrictions were found in the remaining jurisdictions. Prescriber type was restricted to specialists in up to 42% of provinces/territories. INTERPRETATION: This review of criteria of reimbursement of HCV direct-acting antivirals in Canada showed substantial interjurisdictional heterogeneity. The findings could inform health policy and support the development and adoption of a national HCV strategy.
31
EASL Recommendations on Treatment of Hepatitis C 2018
Jean–Michel Pawlotsky, Francesco Negro, Alessio Aghemo et al. · Journal of Hepatology · 2018 · 2.8K citations
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
Eric Lawitz, Alessandra Mangia, David Wyles et al. · New England Journal of Medicine · 2013 · 1.8K citations
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Nezam H. Afdhal, Stefan Zeuzem, Paul Y. Kwo et al. · New England Journal of Medicine · 2014 · 1.7K citations · Full text